Related Experiment Video
Updated: Jul 11, 2026
08:41
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Paclitaxel-eluting stent Taxcor: first application in man
1Batra Hospital & Medical Research Center, Department of Cardiology, New Delhi, India.
Minerva Cardioangiologica
|October 4, 2007
Summary
The Taxcor paclitaxel-eluting stent demonstrated safety and effectiveness in treating de novo coronary lesions over a 6-month period. This study evaluated the novel stent
Area of Science:
- Cardiovascular Medicine
- Interventional Cardiology
- Biomaterials Science
Background:
- Coronary artery disease necessitates effective revascularization strategies.
- Paclitaxel-eluting stents (PES) are crucial in preventing in-stent restenosis.
- The Taxcor stent represents a second-generation PES with a bioactive matrix.
Purpose of the Study:
- To evaluate the safety and efficacy of the Taxcor paclitaxel-eluting stent.
- To assess outcomes at 6 months post-implantation in de novo coronary lesions.
Main Methods:
- A single-center, non-controlled study involving 45 patients with de novo coronary lesions.
- Fifty Taxcor stents were implanted.
- Clinical and angiographic follow-up were conducted at 6 months.
Main Results:
- The Taxcor stent demonstrated favorable angiographic outcomes, including acute lumen gain and minimal late lumen loss.
- No deaths, acute myocardial infarctions, or stent thromboses were reported.
- One patient experienced binary restenosis, successfully treated with repeat intervention.
Conclusions:
- The Taxcor paclitaxel-eluting stent appears safe and effective for treating de novo coronary lesions up to 6 months.
- The bioactive matrix of the Taxcor stent shows promise in clinical application.
